---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-069159"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-22T01:07:03.024168+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# FibroGen Q1 net loss narrows to $16.8M; China sale consideration raised to ~$185M

## Summary
- Total revenue from continuing ops fell to $2.7M from $25.4M YoY; net loss improved to $16.8M ($0.16/sh) from $49.0M.
- Sale of FibroGen China to AstraZeneca now expected total consideration ~$185M (enterprise $85M + net cash ~$100M); close in 3Q-2025.
- Upon China sale close, cash runway extended into 2H 2027; Morgan Stanley term loan to be repaid.
- Phase 2 monotherapy trial of FG-3246 (CD46 ADC) in mCRPC expected to start 3Q-2025; topline combo data from UCSF study due 4Q-2025.
- Filed Type-C meeting request with FDA for roxadustat in LR-MDS anemia; feedback expected in 3Q-2025.

## SEC filing metadata
- accession: 0000950170-25-069159
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000095017025069159/0000950170-25-069159-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000095017025069159/fgen-20250512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-069159
- JSON: https://secwatch.observer/filing/0000950170-25-069159.json
- Plain text: https://secwatch.observer/filing/0000950170-25-069159.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.